Whitehawk Therapeutics, Inc. (WHWK)
Market Cap | 87.15M |
Revenue (ttm) | 27.78M |
Net Income (ttm) | 27.61M |
Shares Out | 47.11M |
EPS (ttm) | 0.91 |
PE Ratio | 2.09 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 82,729 |
Open | 1.920 |
Previous Close | 1.870 |
Day's Range | 1.920 - 1.930 |
52-Week Range | 1.210 - 3.812 |
Beta | 0.59 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Aug 15, 2025 |
About WHWK
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey. [Read more]
Financial Performance
In 2024, Whitehawk Therapeutics's revenue was $25.98 million, an increase of 6.69% compared to the previous year's $24.35 million. Losses were -$63.69 million, -3.15% less than in 2023.
Financial StatementsNews

Whitehawk Therapeutics to Participate in H.C. Wainwright "HCW@Home" Series
MORRISTOWN, N.J. , June 19, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficientl...

Whitehawk Therapeutics to Present at the Jefferies 2025 Global Healthcare Conference
MORRISTOWN, N.J. , May 28, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently...

Whitehawk Therapeutics to Participate in the TD Cowen 6th Annual Oncology Innovation Summit
MORRISTOWN, N.J. , May 21, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently...

Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights
MORRISTOWN, N.J. , May 8, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently ...

Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals
MORRISTOWN, N.J. , March 26, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficient...

Whitehawk Therapeutics Inc. (WHWK) Q4 2024 Earnings Call Transcript
Whitehawk Therapeutics Inc. (NASDAQ:WHWK) Q4 2024 Results Conference Call March 19, 2025 8:30 AM ET Company Participants Audrey Gross - Head of Corporate Communications Dave Lennon - President and Ch...

Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company
New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected to fund operations into 2028 enablin...